Real-world outcomes of brigatinib compared to alectinib as a second-line therapy after crizotinib in advanced anaplastic lymphoma kinase positive non-small cell lung cancer patients

Asan Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年6月24日

试验速览

暂无简介。

•1. Male or female adult patients aged 18 years old and above
•2. Patients who were diagnosed as locally advanced or metastatic NSCLC from Jan 2011
•3. Patients who were diagnosed as histologically or cytologically ALK positive adenocarcinoma
•4. Patients who initiated crizotinib as a first-line therapy and experienced disease progression
•(definitive CCRT, neoadjuvant or adjuvant chemotherapy prior to crizotinib are allowed)
•5. Patients who were treated with crizotinib for at least 84 days
•6. Patients who are eligible to evaluate response to brigatinib or alectinib
•7. Patients who provide written informed consent for the study

•1. Patients who were treated with ALK inhibitors other than alectinib or brigatinib after crizotinib failure
•2. Patients who stopped a first-line crizotinib treatment for other than disease progression
•3. Patients who received chemotherapy in between crizotinib and 2nd line ALK inhibitor
•4. Patients whose medical records are not available for review

发起方